• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
Home
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
    • Emerging Biopharma
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
Search Icon
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
    • Emerging Biopharma
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events

Sinopharm

Biotech

Texas biotech’s COVID booster takes on competitors in phase 3

Vaxxinity’s next-gen COVID-19 booster candidate has hit its safety targets in a head-to-head phase 3 trial.
Gabrielle Masson Dec 2, 2022 11:00am

Sinopharm mulls $1B buy for DNA maker BBI Life Sciences: report

Jul 8, 2022 10:49am

Sinopharm claims COVID-19 vaccine safe in kids aged 3 and up

Jan 15, 2021 9:05am

Chinese biotech Sinovac sees 78% COVID-19 vaccine efficacy

Jan 8, 2021 7:32am

China's Sinopharm sees 79% COVID-19 vaccine efficacy

Dec 30, 2020 9:25am

Sinopharm shares phase 2 data on inactivated COVID-19 vaccine

Aug 14, 2020 6:54am
Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2023 Questex LLC All rights reserved.
Terms of use
Privacy Policy